Leveraging MYC as a therapeutic treatment option for TNBC

Oncoscience. 2018 Jun 24;5(5-6):137-139. doi: 10.18632/oncoscience.424. eCollection 2018 May.

Authors

Jason P W Carey¹, Khandan Keyomarsi¹

Affiliation

¹ Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

No abstract available

Keywords: CDK; MYC; PARP; TNBC; biomarker.

Publication types

Editorial